Frank M. Torti's most recent trade in Immunovant Inc was a trade of 199,365 Common Stock done . Disclosure was reported to the exchange on April 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 199,365 | 835,039 (1%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2025 | 93,599 | 93,599 | - | - | Stock Option (right to buy) | |
| Arbutus Biopharma Corp | Frank M. Torti | Director | 23 May 2024 | 67,000 | 67,000 | - | - | Stock Option (Right to Buy) | ||
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 120,400 | 635,674 (1%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 50,167 | 50,167 | - | - | Stock Option (right to buy) | |
| Arbutus Biopharma Corp | Frank M. Torti | Director | 24 May 2023 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | ||
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 158,292 | 158,292 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 121,916 | 515,274 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Frank M. Torti | Director | Purchase of securities on an exchange or from another person at price $ 5.81 per share. | 29 Sep 2022 | 20,000 | 393,358 (0%) | 0% | 5.8 | 116,200 | Common Stock |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 339,296 | 339,296 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Aug 2022 | 225,632 | 373,358 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | Frank M. Torti | Director | 25 May 2022 | 41,000 | 41,000 | - | - | Stock Option (Right to Buy) | ||
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 329,485 | 554,748 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2022 | 100,126 | 147,726 (0%) | 0% | 0 | Common Stock | |
| Arbutus Biopharma Corp | Frank M. Torti | Director | 03 Jun 2021 | 22,000 | 22,000 | - | - | Stock Options | ||
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 28,900 | 28,900 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Frank M. Torti | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Mar 2021 | 19,200 | 47,600 (0%) | 0% | 0 | Common Stock |